tradingkey.logo
tradingkey.logo

Astrazeneca Says Tozorakimab Meets Primary Endpoint In Oberon And Titania Phase III COPD Trials

ReutersMar 27, 2026 7:21 AM

- AstraZeneca PLC AZN.L:

  • ASTRAZENECA PLC - TOZORAKIMAB MET OBERON/TITANIA PRIMARY ENDPOINTS

  • ASTRAZENECA - TOZORAKIMAB WAS GENERALLY WELL TOLERATED WITH A FAVOURABLE SAFETY PROFILE

  • ASTRAZENECA - TOZORAKIMAB DEMONSTRATES SIGNIFICANT REDUCTION IN COPD EXACERBATIONS IN TWO PHASE III TRIALS

  • ASTRAZENECA - FULL RESULTS FROM OBERON AND TITANIA TRIALS TO BE SHARED AT UPCOMING MEDICAL MEETING

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey

Recommended Articles

Tradingkey
KeyAI